# Genome Editing of Human Primary Keratinocytes by CRISPR/Cas9 Reveals an Essential Role of the NLRP1 Inflammasome in UVB Sensing

Gabriele Fenini<sup>1,4</sup>, Serena Grossi<sup>1,4</sup>, Emmanuel Contassot<sup>1,2</sup>, Thomas Biedermann<sup>3</sup>, Ernst Reichmann<sup>3</sup>, Lars E. French<sup>1,2</sup> and Hans-Dietmar Beer<sup>1,2</sup>

By forming a protective barrier, epidermal keratinocytes represent the first line of defense against environmental insults. UVB radiation of the sun is a major challenge for the skin and can induce inflammation, aging, and eventually skin cancer. UVB induces an immune response in human keratinocytes resulting in activation and secretion of the proinflammatory cytokines proIL-1 $\beta$  and -18. This is mediated by an assembly of protein complexes, termed inflammasomes. However, the mechanisms underlying sensing of UVB by keratinocytes, and particularly the types of inflammasomes required for cytokine secretion, are a matter of debate. To address these questions, we established a protocol that allows the generation of CRISPR/Cas9-targeted human primary keratinocytes. Our experiments showed an essential role of the NLRP1 rather than the NLRP3 inflammasome in UVB sensing and subsequent IL-1 $\beta$  and -18 secretion by keratinocytes. Moreover, NLRP1 but not NLRP3 was required for inflammasome activation in response to nigericin, a potassium ionophore and well-established NLRP3 activator in immune cells. Because the CRISPR/Cas9-targeted cells retained their full differentiation capacity, genome editing of human primary keratinocytes might be useful for numerous research and medical applications.

Journal of Investigative Dermatology (2018) ■, ■-■; doi:10.1016/j.jid.2018.07.016

#### **INTRODUCTION**

Immune cells are able to detect many different stress factors, such as pathogens or endogenous molecules released upon injury. In response to these insults, they initiate an inflammatory response, which helps eliminate the stressors and restore a new homeostatic state (Medzhitov, 2008). Inflammasomes represent multimeric protein complexes, which are critically involved in these processes (Strowig et al., 2012). They consist of a sensor protein, including NLRP1, NLRP3, or AIM2; the adaptor protein ASC, and the protease caspase-1. Assembly of inflammasomes induces activation of caspase-1, which in turn cleaves and thereby activates the proinflammatory cytokines proIL-1 $\beta$  and -18 (Place and Kanneganti, 2017; Strowig et al., 2012). Secretion of these cytokines induces an inflammatory response, which is supported by a lytic type of cell death termed *pyroptosis*. The latter is induced upon cleavage of gasdermin D by inflammatory

caspases, because the amino terminal fragment of gasdermin D forms pores in the plasma membrane upon oligomerization (Kayagaki et al., 2015; Liu et al., 2016; Shi et al., 2015). Inflammasomes are required for immunity but also play a central role in inflammation, underlying many common (auto)inflammatory diseases (Fenini et al., 2017; Strowig et al., 2012).

In immune cells, expression of proIL-1 $\beta$ , NLRP3, or AIM2 must be induced before inflammasome activation, for example by toll-like receptor stimulation (Latz et al., 2013). In contrast, human primary keratinocytes (HPKs) secrete IL-1 $\beta$  and -18 without priming upon UVB irradiation (Feldmeyer et al., 2007; Strittmatter et al., 2016b). Several stress factors, including UVB radiation (Feldmeyer et al., 2007; Hasegawa et al., 2016), cytoplasmic double-stranded DNA (Dombrowski et al., 2011), nanoparticles (Yazdi et al., 2010), or viral infection (Reinholz et al., 2013; Strittmatter et al., 2016b), are reported to induce inflammasome activation in HPKs.

Although it has been reported that HPKs do not express NLRP3 and that NLRP1 represents the important inflammasome sensor in these cells (Zhong et al., 2016), several groups suggested a role of the NLRP3 or AIM2 inflammasome in human keratinocytes (Dai et al., 2011, 2017; Dombrowski et al., 2011; Feldmeyer et al., 2007; Strittmatter et al., 2016b). In these studies, expression of inflammasome components was targeted by RNA interference. However, it is well known that RNA molecules can modulate the innate immune system, for example via the toll-like receptor pathway, and therefore can possibly influence inflammasome expression and activity (Agrawal and Kandimalla, 2004; Robbins et al., 2009). Consequently, the role of specific inflammasome sensors in human primary keratinocytes

<sup>&</sup>lt;sup>1</sup>Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; <sup>2</sup>Faculty of Medicine, University of Zurich, Zurich, Switzerland; and <sup>3</sup>Tissue Biology Research Unit, University Children's Hospital Zurich, Zurich, Switzerland

<sup>&</sup>lt;sup>4</sup>These authors contributed equally to this work.

Correspondence: Hans-Dietmar Beer, Gloriastrasse 31, CH-8091, Zürich, Switzerland. E-mail: Hans-Dietmar.Beer@usz.ch

Abbreviations: BPE, bovine pituitary extract; DPBS, Dulbecco's phosphatebuffered saline; EGF, epidermal growth factor; HPK, human primary keratinocyte; KSFM, serum-free keratinocyte medium; RGM, Rheinwald and Green medium; sgRNA, single guide RNA; shRNA, short hairpin RNA; siRNA, small interfering RNA

Received 27 March 2018; revised 21 June 2018; accepted 6 July 2018; accepted manuscript published online 7 August 2018; corrected proof published online XXX

# G Fenini et al.

Ablation of *NLRP1* in human keratinocytes

should be addressed by approaches different from small interfering RNA (siRNA)- or short hairpin (shRNA)-mediated knockdown. Activating mutations in the gene encoding NLRP1 cause skin inflammation induced by hyperactivation of the inflammasome in keratinocytes and thereby increase the risk of developing skin cancer, showing that inflammasome activation in human keratinocytes is also highly relevant in vivo (Zhong et al., 2016). In contrast, murine keratinocytes neither express detectable amounts of proIL-1 $\beta$  protein nor assemble functional inflammasomes (Sand et al., 2018).

Isolation and propagation of keratinocytes, including epidermal stem cells, is a well-established method, which requires co-culture in the presence of mitotically-inactivated murine fibroblasts as feeder cells (Rheinwald and Green, 1975). Genetic manipulation of HPKs represents a useful tool for targeted gene therapy of diseases affecting keratinocytes. Recently, it has been shown that epidermal stem cells from a patient suffering from junctional epidermolysis bullosa, a devastating disease caused by a defective LAMB3 gene, can be "corrected" upon transduction with a retroviral vector encoding the wild-type protein (Mavilio et al., 2006). Furthermore, through production of autologous epidermal sheets with the help of feeder cells, even the entire epidermis of a 7-year-old boy could be replaced by wild-type LAMB3overexpressing keratinocytes (Hirsch et al., 2017). However, genome editing via the CRISPR/Cas9 approach would allow a more specific genetic modification of keratinocytes and, in principle, gene therapy for other genetic diseases affecting keratinocytes of the epidermis (Doudna and Charpentier, 2014; Zhang et al., 2014). In addition, direct targeting of human primary keratinocytes by CRISPR/Cas9 would represent a very useful tool for answering many scientific, medical, and pharmacological questions in dermatological research.

Here, we developed and optimized a protocol for the generation of knockout HPKs with the CRISPR/Cas9 technology. Genetic modification and selection of the targeted keratinocytes was achieved by co-culture with antibiotic-resistant and proliferation-incompetent murine fibroblasts. CRISPR/Cas9-targeted keratinocytes retained the ability of differentiation and were able to form three-dimensional skin equivalents. The comparison of keratinocytes lacking either NLRP1, NLRP3, or ASC expression showed an essential role of the NLRP1 inflammasome in UVB- and nigericin-induced IL-1 $\beta$  and -18 secretion.

#### RESULTS

# Establishment of a protocol for stable genetic modification of keratinocytes

Isolation of HPKs from skin biopsy samples (Rasmussen et al., 2013; Rheinwald and Green, 1975) or plucked hair (Aasen and Izpisua Belmonte, 2010) is well established, and the culture of HPKs represents a physiologically relevant model in dermatologic research (Strittmatter et al., 2016a). Isolation and propagation of HPKs on coated or noncoated surfaces with special low-Ca<sup>2+</sup> and serum-free media is simple and suppresses growth of other skin-derived cells, such as fibroblasts, Langerhans cells, or melanocytes (Zare et al., 2014). However, under these culturing conditions, HPKs are prone to terminal differentiation and stop proliferation after a few passages. In contrast, cultivation of HPKs in the presence of

proliferation-incompetent 3T3 fibroblasts strongly increases their lifetime. In particular, the clone 3T3-J2 has been used for propagation of keratinocytes. However, these co-cultures are more elaborate than monocultures (Rasmussen et al., 2013; Strittmatter et al., 2016a).

Genetic manipulation of HPKs is a useful tool for dermatological research, and the method of choice is lentiviral transduction (Nanba et al., 2013), because transfection of plasmid DNA is highly toxic and can cause inflammasome activation (Strittmatter et al., 2016b).

We developed and optimized a protocol for the stable genetic modification of HPKs (Figure 1) based on their lentiviral transduction and co-culture with 3T3-J2 feeder cells. After separation of epidermis and dermis from a skin biopsy sample, keratinocytes were isolated from the epidermal layer upon enzymatic digestion with trypsin and seeded onto mitotically-inactivated (proliferation-incompetent) feeder cells in the presence of the ROCK inhibitor Y-27632 (day 1). Culture in the presence of this inhibitor enhances the survival and proliferation of epidermal stem cells (Nanba et al., 2013; Strudwick et al., 2015) and is therefore maintained until the first trypsinization. After medium change (day 2), HPKs were transduced with lentiviruses at day 3 in the presence of polybrene (hexadimethrine bromide). Two days and a medium change later, the remaining feeder cells were gently removed with a diluted trypsin/EDTA solution, and HPKs were detached by standard trypsinization and seeded on a new layer of puromycin-resistant and mitotically-inactivated feeder cells (day 5) in the presence of the ROCK inhibitor. The optimal density for trypsinization of HPKs was 50%-60%, but not higher than 70%, because confluent cells irreversibly lose their proliferative capacity (see Supplementary Figure S1 online). Transduction of HPKs with a lentiviral construct encoding a single guide RNA (sgRNA) targeting the ASC gene and encoding Cas9 resulted in almost complete ablation of ASC expression by selecting the transduced HPKs with high concentrations of puromycin (5  $\mu$ g/ml) for 1 week (Figure 2a and b). Prolonged selection of HPKs with puromycin rather than high concentrations for a few days negatively influenced their long-term survival (results not shown).

In brief, we successfully established a protocol for the efficient stable genetic modification of HPKs. This was achieved by lentiviral transduction and selection of transduced cells with antibiotics in co-culture with antibiotic-resistant feeder cells. This protocol allows the generation of CRISPR/Cas9-mediated knockout HPKs but also of HPKs that over-express proteins in an inducible or constitutive manner (data not shown).

### Characterization of knockout HPKs

Using the described protocol, we targeted expression of genes encoding the inflammasome proteins caspase-1 or ASC in HPKs. Western blots of the cell lysates of targeted cells showed a dramatic reduction in caspase-1 or ASC protein expression (Figure 2c). ASC and caspase-1 expression are required for UVB-induced inflammasome activation in HPKs (Feldmeyer et al., 2007). To assess whether the generated CRISPR/Cas9targeted HPKs are able to form a functional inflammasome, we irradiated these cells with UVB and analyzed IL-1 $\beta$  secretion as a readout for inflammasome activation. As expected, in

# **ARTICLE IN PRESS**

# G Fenini et al.

Ablation of NLRP1 in human keratinocytes



Figure 1. Workflow for the generation of CRISPR/Cas9-targeted human primary keratinocytes (HPKs).

(a) On day 0, mitotically inactivated 3T3-J2 feeder cells were seeded at a density of 50%. (b) At day 1, freshly isolated HPKs were added (ratio of HPKs:J2 = 5:1), and (c) the medium was changed after 24 hours. (d) Clones of 5 or 6 HPKs were transduced with lentiviral vectors encoding sgRNA and Cas9, and (e) the medium was changed after 24 hours. (f) HPKs were grown until they reached an optimal density of 50% -60%; (g) feeder cells were removed by a short incubation with diluted trypsin/EDTA solution, and keratinocytes were trypsinized and seeded on fresh mitotically inactivated puromycin-resistant feeder cells. Selection started 24 hours after splitting. Scale bars =  $100 \ \mu m$ ; red dashed lines highlight keratinocyte clones. hrs, hours.

after trypsin/EDTA

ASC and caspase-1 sgRNA CRISPR/Cas9-targeted HPKs, IL-1 $\beta$  secretion was strongly reduced compared with control cells, as shown by Western blot (Figure 2c) and ELISA (Figure 2d). This confirms earlier results obtained by siRNA-mediated knockdown experiments (Feldmeyer et al., 2007). Very importantly, control CRISPR/Cas9-targeted HPKs, which were transduced with a nontargeting sgRNA, secreted similar amounts of IL-1 $\beta$  as nontransduced wild-type cells. These results show that lentiviral transduction and selection of transduced HPKs by puromycin do not affect their ability to form active inflammasomes. Therefore, CRISPR/Cas9 targeting and manipulation of HPKs is a useful tool for investigating inflammasome activation in these cells.

Furthermore, we addressed the question of whether the CRISPR/Cas9-targeted HPKs retain full differentiation capacity. Ablation of ASC expression in epidermal keratinocytes of mice does not cause a spontaneous phenotype, showing that it is not required for differentiation of murine keratinocytes (Drexler et al., 2012). Likewise, cultivation in the absence of epidermal growth factor (EGF) induced differentiation of control, caspase-1, and ASC sgRNA CRISPR/Cas9-targeted HPKs in a similar manner and, most importantly, comparable to wild-type keratinocytes (Figure 2e). Indeed, wild-type, control, caspase-1, and ASC sgRNA CRISPR/Cas9-targeted HPKs induced expression of early differentiation markers, such as keratin 1 and keratin 10, but also of filaggrin and involucrin, which are expressed in the stratum granulosum and stratum corneum, after 3 days in culture without EGF. When cultivated on collagen gels containing human primary fibroblasts, HPKs form a three-dimensional structure, resembling characteristic features of the epidermis in vivo (Pontiggia et al., 2009). To test whether our protocol is compatible with stratification and three-dimensional differentiation of HPKs in skin equivalents, we seeded wild-type and ASC sgRNA CRISPR/ Cas9-targeted HPKs on top of a collagen-based dermal equivalent. After 2 weeks in culture, both preparations resulted in skin equivalents with a stratified epidermis-like structure (see Supplementary Figure S2 online). These experiments show that sgRNA CRISPR/Cas9-targeted HPKs are able to differentiate in two- and three-dimensional culture in vitro and therefore, most likely, also in vivo.

# UVB activates the NLRP1 rather than the NLRP3 inflammasome in HPKs

Recently, it has been suggested that NLRP1 is the predominant inflammasome sensor in human keratinocytes (Zhong et al.,

# **ARTICLE IN PRESS**

# G Fenini et al.

Ablation of NLRP1 in human keratinocytes



**Figure 2. Generation and characterization of CRISPR/Cas9-targeted HPKs. (a)** Western blot analysis and (**b**) quantification of ASC bands using lysate of HPKs transduced with a lentiviral vector targeting the ASC gene or a nontargeting sgRNA (control) and cultured under puromycin selection as indicated. (**b**) The intensities of ASC bands on Western blots were normalized to β-actin protein levels and are shown relative to the levels seen in control sgRNA-targeted CRISPR/Cas9 HPKs. sgRNA-targeted genes and antibodies used for Western blots are indicated. (**c**) Western blot analysis of cell lysate (CL) and supernatant (SN) of nontargeting control, caspase-1, and ASC sgRNA CRISPR/Cas9-targeted HPKs or wild-type cells maintained on feeder cells. (**d**) ELISA for IL-1β quantification in supernatants of untreated and UVB-irradiated control, caspase-1, and ASC sgRNA CRISPR/Cas9-targeted HPKs and wild-type keratinocytes. \**P* ≤ 0.05. (**e**) Western blot analysis using cell lysate of control, caspase-1, and ASC sgRNA CRISPR/Cas9-targeted HPKs and wild-type HPKs. Cells were harvested at the exponential growth phase (exp) and when reaching confluency (conf), both in keratinocyte medium, or after the indicated days in keratinocyte differentiation medium (DM). sgRNA-targeted genes and antibodies used for Western blots are indicated. Data are expressed as the mean ± standard error of the mean of three independent experiments using two-way analysis of variance with Dunnett multiple comparison test (in **d**) or are representative of three independent experiments (in **c**). HPK, human primary keratinocyte; K, keratin; ns, not significant; sgRNA, single guide RNA; wt, wild type.

2016). In contrast, other publications also showed important roles of the NLRP3 and AIM2 inflammasomes in HPKs (Dombrowski et al., 2011; Feldmeyer et al., 2007; Hasegawa et al., 2016; Reinholz et al., 2013). An siRNA approach suggested that both NLRP1 and NLRP3 contribute to UVB-induced IL-1 $\beta$  secretion in HPKs (Feldmeyer et al., 2007). On

the other hand, pharmacological inhibition of the NLRP3 inflammasome had no effect on IL-1 $\beta$  release by HPKs (Fenini et al., 2018). To address this inconsistency, we generated NLRP1 and NLRP3 sgRNA CRISPR/Cas9-targeted HPKs, using two different sgRNAs; ASC sgRNA CRISPR/Cas9-targeted cells served as control. Gene targeting was assessed 5 days after

# **ARTICLE IN PRESS**

# G Fenini et al.

Ablation of NLRP1 in human keratinocytes



**Figure 3.** NLRP1, but not NLRP3, has a key role in sensing UVB radiation and nigericin in HPKs. (a) Nontargeting control, ASC, NLRP1 (two sequences), and NLRP3 (two sequences) CRISPR/Cas9-targeted HPKs were either primed overnight with IFNγ (20 ng/ml) or left untreated. Western blot analysis using cell lysate

## *G Fenini* et al.

Ablation of NLRP1 in human keratinocytes

transduction by genomic cleavage detection assays (see Supplementary Figure S3 online). Protein down-regulation was confirmed by Western blots (Figure 3a). Expression of NLRP3 can be detected only upon priming with IFN $\gamma$ (Strittmatter et al., 2016b). Under this condition, NLRP3 protein expression was absent in NLRP3 sgRNA CRISPR/Cas9targeted cells. Western blots showed that expressions of caspase-1, ASC, proIL-1 $\beta$ , and proIL-18 were not affected by ablation of NLRP1 and NLRP3 (Figure 3a). When exposed to UVB, ASC and NLRP1 but not NLRP3 CRISPR/Cas9-targeted HPKs showed a strongly reduced inflammasome activation, even after priming with IFN $\gamma$ , as reflected by the diminished IL-1 $\beta$  and -18 secretion (Figure 3b-d) and lactate dehydrogenase release (Figure 3e). Nigericin is a well-established stimulus for NLRP3 inflammasome activation in immune cells (Mariathasan et al., 2006). NLRP3 depletion in HPKs did not influence IL-1 $\beta$  release upon treatment with nigericin. In contrast, ablation of NLRP1 expression impaired IL-1 $\beta$  and -18 secretion in a similar manner as targeting of ASC expression (Figure 3b-d). As expected, targeting of ASC, but not of NLRP1 or NLRP3, impaired cytokine secretion in response to poly(deoxyadenylicdeoxythymidylic) acid sodium salt (i.e., poly[dA:dT]), an AIM2 inflammasome activator (see Supplementary Figure S5 online). These experiments suggest that NLRP1 rather than NLRP3 is the key inflammasome sensor in HPKs.

## **DISCUSSION**

By inducing inflammation, inflammasomes play a fundamental role in immunity and in many different common (auto)inflammatory diseases, ranging from diabetes to atherosclerosis (Larsen et al., 2007; Ridker et al., 2017; Strowig et al., 2012). Upon the detection of a broad variety of danger signals, they mount an immune response by activation of caspase-1 and in turn by release of mature IL-1 $\beta$  and -18. Inflammasome components are mainly expressed by immune cells upon priming, like toll-like receptor signaling, which induces expression of proIL-1 $\beta$  and other inflammasome components such as NLRP3 and AIM2 (Place and Kanneganti, 2017; Strowig et al., 2012). Furthermore, IL-1β secretion can also be induced in HPKs by UVB irradiation, which does not require a specific priming signal (Faustin and Reed, 2008; Feldmeyer et al., 2007). UVB is a major threat for epidermal keratinocytes and induces inflammation, skin aging, and eventually skin cancer. How HPKs sense UVB radiation is poorly understood, but studies based on siRNAor shRNA-mediated knockdown experiments suggested a role of both the NLRP1 and NLRP3 inflammasomes (Feldmeyer et al., 2007; Hasegawa et al., 2016).

Mice are a frequently used model in biological and medical research, including skin studies. However, in contrast to HPKs, previous studies suggest that murine keratinocytes neither express prolL-1 $\beta$  nor form active inflammasomes (Sand et al., 2018). In addition, caspase-1 is a regulator of UVB-induced apoptosis in HPKs but is dispensable for this process in murine keratinocytes and in the epidermis of these animals (Sollberger et al., 2015). Therefore, there are important differences concerning the role of inflammasomes in human versus murine keratinocytes and skin. Recently, it was reported that activating mutations in the NLRP1 gene cause skin inflammation in humans, which is mediated by inflammasome activation in keratinocytes (Zhong et al., 2016). Because expression of NLRP3 in HPKs and in human skin could not be detected, it was concluded that NLRP1 is the most important inflammasome sensor in human keratinocytes (Zhong et al., 2016), in contrast to several other reports based on siRNA and shRNA experiments (Dombrowski et al., 2011; Feldmeyer et al., 2007; Hasegawa et al., 2016; Reinholz et al., 2013; Strittmatter et al., 2016b; Watanabe et al., 2007; Yazdi et al., 2010). Because it is well known that siRNA and shRNA can induce and modulate immune responses relevant for the inflammasome pathway (Agrawal and Kandimalla, 2004; Robbins et al., 2009), we targeted ASC, caspase-1, NLRP1, and NLRP3 expression by sgRNA and CRISPR/Cas9. In contrast to siRNA and shRNA approaches, genome editing of HPKs with CRISPR/Cas9 has much less severe effects on immune pathways, including inflammasomes. Most important, in contrast to NLRP3 sgRNA CRISPR/Cas9-targetd HPKs, those with ablated ASC or NLRP1 expression secreted drastically reduced levels of IL-1 $\beta$ upon UVB irradiation and upon treatment with nigericin compared with the corresponding control cells. This shows that NLRP1 rather than NLRP3 is the main inflammasome sensor of HPKs, as also recently suggested (Fenini et al., 2018). The importance of NLRP1 in human skin is also supported by other reports showing a susceptibility to skin inflammation and autoimmunity, such as vitiligo and psoriasis, caused by variations in NLRP1 (Ekman et al., 2014; Jin et al., 2007a, 2007b; Levandowski et al., 2013). It has been suggested that particularly mouse NLRP1 can directly activate caspase-1 by CARD-CARD interactions independently of ASC expression, although the presence of ASC further supports activation of the protease (Van Opdenbosch et al., 2014; Yu et al., 2018). In contrast, ASC CRISPR/Cas9targeted HPKs did not secrete IL-1 $\beta$  upon UVB radiation (Figure 2c and d and Figure 3a-e), showing that in HPKs, ASC expression is needed for NLRP1 inflammasome activation.

We established a protocol for sgRNA CRISPR/Cas9targeting of HPKs. HPKs represent an established model for many different research and medical applications. They are frequently used in monoculture or in conjunction with dermal fibroblasts in more sophisticated three-dimensional models, where keratinocytes form a stratified epithelium,

<sup>(</sup>CL) of mock-treated cells. (b) Supernatant (SN) of UVB-irradiated and nigericin-treated cells was analyzed by Western blot for secretion of the indicated proteins. Quantification of band signal intensity of secreted mature IL-1 $\beta$  and IL-18 normalized to the corresponding untreated samples from three independent experiments (c, and see Supplementary Figure S4 online). Supernatant (SN) of UVB-irradiated and nigericin-treated cells was analyzed by ELISA (d) for IL-1 $\beta$  secretion levels or (e) for lactate dehydrogenase release. sgRNA-targeted genes and antibodies used for Western blots are indicated. Data are expressed as the mean  $\pm$  standard error of the mean of four (in d and e) or three (in c) independent experiments using one-way analysis of variance with Dunnett multiple comparison test (in d and e) or are representative of three independent experiments (in a). \* $P \le 0.05$ , \*\* $P \le 0.01$  and \*\*\* $P \le 0.001$ . HPK, human primary keratinocyte; sgRNA, single guide RNA.

Ablation of NLRP1 in human keratinocytes

resembling human skin (Pontiggia et al., 2009). However, HPKs in monoculture undergo differentiation after few passages, thus limiting their applications. The use of fibroblasts as feeder cells extends the lifespan of HPKs and is the method of choice when large amounts of HPKs are required (Rasmussen et al., 2013; Rheinwald and Green, 1975). Recently, CRISPR/Cas9 technology was used to correct a mutation in the *COL7A1* gene causing dominant (Shinkuma et al., 2016) and recessive (Webber et al., 2016) dystrophic epidermolysis bullosa in vitro. Patient-derived fibroblasts or induced pluripotent stem cells were targeted by CRISPR/ Cas9, differentiated into keratinocytes, and expanded on feeder cells.

Our approach, instead, targets HPKs directly, requires less manipulation of the cells, and allows their selection. However, for the future, improvements of our protocol, particularly for gene therapeutic applications, are necessary. HPKs should be expanded after genetic modification by CRISPR/ Cas9 from single cells, allowing the selection of true knockouts and even knockins and their characterization by sequencing. Lentiviral or retroviral integration can disrupt genetic information, resulting in aberrant transcripts and possibly leading to cancer development (Hirsch et al., 2017; Moiani et al., 2012; Qian et al., 2017). This can be avoided using other currently available approaches, such as transfection of the recombinant Cas9 protein with the sgRNA of interest.

Here, we show successful sgRNA CRISPR/Cas9-targeting of HPKs. The modification of HPKs by CRISPR/Cas9 has the potential to result in excellent research models, for example, in combination with human skin equivalents. This is strongly required because of obvious limitations of animal experimentation. In addition, several applications in human patients are conceivable, which go far beyond the treatment of epidermolysis bullosa.

#### MATERIALS AND METHODS Cell culture

HEK 293T cells (CRL-3216; ATCC, Manassas, VA), 3T3-J2 feeder cells (CRL-1658, ATCC) and 3T3-J2 puromycin-resistant feeder cells were cultured in DMEM (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (PAN-Biotech, Aidenbach, Germany) and 1% antibiotic/antimycotic (Thermo Fisher Scientific). Cells were harvested with trypsin/EDTA solution (0.05%/ 0.02% weight/volume) (Thermo Fisher Scientific).

Co-cultures of HPKs and 3T3-J2 feeder cells were performed in Rheinwald and Green medium (RGM): three parts DMEM, one part HAM's F12 Nutrient Mixture (Thermo Fisher Scientific), 10% fetal bovine serum, 1% antibiotic/antimycotic, 20 µg/ml adenine (Sigma-Aldrich, St. Louis, MO), 5 µg/ml apo-transferrin (Sigma-Aldrich), 2 nmol/L 3,3',5-triiodothyronin (Sigma-Aldrich), 200 ng/ml hydrocortisone (Sigma-Aldrich), 100 pg/ml cholera toxin (Sigma-Aldrich), 5 µg/ml insulin (Sigma-Aldrich), and 10 ng/ml EGF (Sigma-Aldrich). HPKs were trypsinized at an optimal density of 50%–60%. Before trypsinization of HPKs, 3T3-J2 feeder cells were removed by short incubation with diluted trypsin/EDTA solution (0.005%/0.05% weight/volume in Dulbecco's phosphate-buffered saline (DPBS)). HPKs were detached with trypsin/EDTA solution (0.05%/0.02% weight/volume) and seeded onto a new layer of mitotically inactivated 3T3-J2 feeder cells in RGM supplemented with 10 µmol/L ROCK1 inhibitor (Y-27632 2HCl, Selleckchem, Houston, TX). After 24 hours the medium was changed to standard RGM, and HPKs were maintained in co-culture with 3T3-J2 feeder cells until the experiment.

Monocultures of HPKs were grown in serum-free keratinocyte medium (KSFM) Thermo Fisher Scientific) supplemented with EGF and bovine pituitary extract (BPE). Cells were harvested as described and cultured for at least 48 hours before the experiment. All cells were incubated at 37 °C in 5%  $CO_2$  and 95% humidity.

### Manipulation of cells

3T3-J2 puromycin-resistant feeder cells were generated to allow selection of co-cultured lentivirally transduced HPKs. 3T3-J2 feeder cells were transduced with pLenti CMVtight Puro DEST (w768-1) (#26430, Addgene) and selected with 5  $\mu$ g/ml puromycin (Sigma-Aldrich).

To inhibit cell proliferation, 3T3-J2 and 3T3-J2 puromycinresistant feeder cells were treated for 2 hours at 37 °C with 10  $\mu$ g/ ml mitomycin C (Santa Cruz Biotechnology) diluted in growth medium. Cells were washed three times with DPBS, trypsinized as described, and plated in growth medium at a density of 50%.

### Isolation of HPKs from skin biopsy samples

Skin biopsy samples were disinfected by a short incubation with 70% ethanol and washed in DPBS. Fat was removed, and the remaining tissue was cut into small pieces. The skin pieces were incubated for 2 hours in DMEM containing 1% antibiotic/antimycotic and subsequently overnight in 4 U/ml Dispase II (Roche, Rotkreuz, Switzerland) in DPBS at 4 °C. Separation of dermis and epidermis was performed the next day, and the epidermis was incubated for 20 minutes at 37 °C in trypsin/EDTA solution (0.25%/ 0.02%). A single cell suspension of keratinocytes was obtained by pipetting the epidermis up and down in DMEM containing 25% fetal bovine serum and 1% antibiotic/antimycotic and passing the cell suspension through a 100-µm nylon strainer (BD, Franklin Lakes, NJ). Cells were centrifuged (170g, 3 minutes, room temperature), resuspended, and plated onto mitotically inactivated 3T3-J2 feeder cells (with a 5:1 ratio) in RGM without EGF supplemented with 10 µmol/L ROCK1 inhibitor.

Skin biopsy samples were collected with informed written consent upon approval from the local ethical committees and were conducted according to the Declaration of Helsinki principles.

## Generation of CRISPR/Cas9-targeted HPKs

sgRNAs were designed using the Benchling platform (https:// benchling.com), and single-stranded DNA oligonucleotides (see Supplementary Table S1 online) purchased from Microsynth (Balgach, Switzerland) were cloned into the lentiCRISPRv2 plasmid (#52961, Addgene) (Sanjana et al., 2014). Plasmids were cotransfected into HEK 293T cells with the packaging vectors psPAX2 (#12260, Addgene) and pMD2.G (#12259, Addgene), and 48 hours later lentiviruses were harvested and concentrated by centrifugation (16,000g, 4 hours, 4 °C). HPKs co-cultured with 3T3-J2 feeder cells were transduced 2 days after isolation. Concentrated viruses were dissolved in RGM containing 10 µmol/L ROCK1 inhibitor and 2.5 µg/ml polybrene (hexadimethrine bromide) (Sigma-Aldrich). Medium was changed 24 hours after transduction to RGM containing 10 µmol/L ROCK1 inhibitor. HPKs were split 4-5 days after isolation and seeded onto a fresh layer of mitotically inactivated 3T3-J2 puromycin-resistant feeder cells in RGM containing 10 µmol/ L Y-27632. After 24 hours medium was changed to RGM containing

# G Fenini et al.

Ablation of *NLRP1* in human keratinocytes

5 µg/ml puromycin (Sigma-Aldrich). Selection was performed for 48 hours. CRISPR/Cas9 targeting efficiency was assessed at the genomic level by processing the DNA with the Genomic Cleavege Detection Kit (Thermo Fisher Scientific) or at the protein level by Western blot.

#### Inflammasome activation in HPKs

For experiments, trypsinized HPKs were resuspended in KSFM supplemented with EGF and BPE and containing 10  $\mu$ mol/L Y-27632. After 24 hours medium was changed to KSFM (supplemented with EGF and BPE), and cells were grown until 70% density.

For priming, HPKs were exposed overnight to 20 ng/ml human IFN $\gamma$  (Peprotech, Rocky Hill, NJ).

Before inflammasome activation, medium was exchanged by fresh KSFM (supplemented with EGF and BPE). HPKs were either left untreated, irradiated with 86.4 mJ/cm<sup>2</sup> UVB (UV802L; Waldmann, Villingen-Schwenninge, Germany), stimulated with 5  $\mu$ mol/L nigericin (Selleckchem, Houston, TX), or transfected with 2  $\mu$ g/ml poly(dA:dT) (InvivoGen, San Diego, CA).

#### In vitro differentiation of HPKs

HPKs were grown in KSFM (supplemented with EGF and bovine pituitary extract) and at 100% confluency, medium was replaced by keratinocyte basal medium chemically defined (Lonza, Basel, Switzerland), supplemented with 0.1 mmol/L ethanolamine and 0.1 mmol/L phosphoethanolamine.

#### Statistical analysis

Statistical analysis was performed using unpaired Student *t* test or one-way analysis of variance followed by Dunnett's multiple comparison test using Prism software (GraphPad, La Jolla, CA). Differences were considered significant when:  $*P \le 0.05$ ,  $**P \le 0.01$  and \*\*\*P < 0.001.

#### **ORCIDs**

Gabriele Fenini: http://orcid.org/0000-0002-5778-936X Serena Grossi: http://orcid.org/0000-0001-9932-4045

#### **CONFLICT OF INTEREST**

The authors state no conflict of interest.

#### ACKNOWLEDGMENTS

We thank Annalisa Saltari for her advice and help in the isolation of HPKs. This work was supported by grants from the Wilhelm Sander-Stiftung, the Promedica Stiftung, the OPO-Stiftung, the Julius Müller Stiftung, and the Kurt und Senta Herrmann-Stiftung to HDB, the Swiss National Science Foundation (31003A-120400 and 310030-156384) and the Zurich University Research Priority Program "Translational Cancer Research" to LEF, and the Zurich University Forschungskredit Candoc to GF. GF and SG were members of the Life Science Zurich Graduate School.

#### SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at www. jidonline.org, and at https://doi.org/10.1016/j.jid.2018.07.016.

#### REFERENCES

- Aasen T, Izpisua Belmonte JC. Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. Nat Protoc 2010;5:371–82.
- Agrawal S, Kandimalla ER. Role of Toll-like receptors in antisense and siRNA [corrected] Nat Biotechnol 2004;22:1533-7.
- Dai X, Sayama K, Tohyama M, Shirakata Y, Hanakawa Y, Tokumaru S, et al. Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes. J Allergy Clin Immunol 2011;127:806–14.
- Dai X, Tohyama M, Murakami M, Sayama K. Epidermal keratinocytes sense dsRNA via the NLRP3 inflammasome, mediating interleukin (IL)-1beta and IL-18 release. Exp Dermatol 2017;26:904–11.

- Dombrowski Y, Peric M, Koglin S, Kammerbauer C, Goss C, Anz D, et al. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Sci Transl Med 2011;3(82):82ra38.
- Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014;346(6213):1258096.
- Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, et al. Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci USA 2012;109:18384–9.
- Ekman AK, Verma D, Fredrikson M, Bivik C, Enerback C. Genetic variations of NLRP1: susceptibility in psoriasis. Br J Dermatol 2014;171:1517–20.
- Faustin B, Reed JC. Sunburned skin activates inflammasomes. Trends Cell Biol 2008;18:4–8.
- Feldmeyer L, Keller M, Niklaus G, Hohl D, Werner S, Beer HD. The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol 2007;17:1140–5.
- Fenini G, Contassot E, French LE. Potential of IL-1, IL-18 and inflammasome inhibition for the treatment of inflammatory skin diseases. Front Pharmacol 2017;8:278.
- Fenini G, Grossi S, Gehrke S, Beer HD, Satoh TR, Contassot E, et al. The p38 mitogen-activated protein kinase critically regulates human keratinocyte inflammasome activation. J Invest Dermatol 2018;138:1380–90.
- Hasegawa T, Nakashima M, Suzuki Y. Nuclear DNA damage-triggered NLRP3 inflammasome activation promotes UVB-induced inflammatory responses in human keratinocytes. Biochem Biophys Res Commun 2016;477:329–35.
- Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature 2017;551(7680):327–32.
- Jin Y, Birlea SA, Fain PR, Spritz RA. Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol 2007a;127:2558–62.
- Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007b;356:1216–25.
- Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 2015;526(7575):666–71.
- Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517–26.
- Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013;13:397–411.
- Levandowski CB, Mailloux CM, Ferrara TM, Gowan K, Ben S, Jin Y, et al. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1beta processing via the NLRP1 inflammasome. Proc Natl Acad Sci USA 2013;110:2952–6.
- Liu X, Zhang Z, Ruan J, Pan Y, Magupalli VG, Wu H, et al. Inflammasomeactivated gasdermin D causes pyroptosis by forming membrane pores. Nature 2016;535(7610):153–8.
- Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006;440(7081):228–32.
- Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med 2006;12: 1397–402.
- Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454(7203):428-35.
- Moiani A, Paleari Y, Sartori D, Mezzadra R, Miccio A, Cattoglio C, et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J Clin Invest 2012;122:1653–66.
- Nanba D, Matsushita N, Toki F, Higashiyama S. Efficient expansion of human keratinocyte stem/progenitor cells carrying a transgene with lentiviral vector. Stem Cell Res Ther 2013;4:127.
- Place DE, Kanneganti TD. Recent advances in inflammasome biology. Curr Opin Immunol 2017;50:32-8.
- Pontiggia L, Biedermann T, Meuli M, Widmer D, Bottcher-Haberzeth S, Schiestl C, et al. Markers to evaluate the quality and self-renewing potential

of engineered human skin substitutes in vitro and after transplantation. J Invest Dermatol 2009;129:480-90.

- Qian W, Wang Y, Li RF, Zhou X, Liu J, Peng DZ. Prolonged integration site selection of a lentiviral vector in the genome of human keratinocytes. Med Sci Monit 2017;23:1116–22.
- Rasmussen C, Thomas-Virnig C, Allen-Hoffmann BL. Classical human epidermal keratinocyte cell culture. Methods Mol Biol 2013;945:161–75.
- Reinholz M, Kawakami Y, Salzer S, Kreuter A, Dombrowski Y, Koglin S, et al. HPV16 activates the AIM2 inflammasome in keratinocytes. Arch Dermatol Res 2013;305:723–32.
- Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975;6:331–43.
- Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–31.
- Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009;19:89–102.
- Sand J, Haertel E, Biedermann T, Contassot E, Reichmann E, French LE, et al. Expression of inflammasome proteins and inflammasome activation occurs in human, but not in murine keratinocytes. Cell Death Dis 2018;9(2):24.
- Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 2014;11:783-4.
- Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015;526(7575):660–5.
- Shinkuma S, Guo Z, Christiano AM. Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa. Proc Natl Acad Sci USA 2016;113: 5676–81.
- Sollberger G, Strittmatter GE, Grossi S, Garstkiewicz M, Auf dem Keller U, French LE, et al. Caspase-1 activity is required for UVB-induced apoptosis of human keratinocytes. J Invest Dermatol 2015;135:1395–404.
- Strittmatter GE, Garstkiewicz M, Sand J, Grossi S, Beer HD. Human primary keratinocytes as a tool for the analysis of caspase-1-dependent unconventional protein secretion. Methods Mol Biol 2016a;1459:135–47.

- Strittmatter GE, Sand J, Sauter M, Seyffert M, Steigerwald R, Fraefel C, et al. IFN-gamma Primes Keratinocytes for HSV-1-Induced Inflammasome Activation. J Invest Dermatol 2016b;136:610–20.
- Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012;481(7381):278–86.
- Strudwick XL, Lang DL, Smith LE, Cowin AJ. Combination of low calcium with Y-27632 rock inhibitor increases the proliferative capacity, expansion potential and lifespan of primary human keratinocytes while retaining their capacity to differentiate into stratified epidermis in a 3D skin model. PLoS One 2015;10(4):e0123651.
- Van Opdenbosch N, Gurung P, Vande Walle L, Fossoul A, Kanneganti TD, Lamkanfi M. Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation. Nat Commun 2014;5:3209.
- Watanabe H, Gaide O, Petrilli V, Martinon F, Contassot E, Roques S, et al. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 2007;127:1956–63.
- Webber BR, Osborn MJ, McElroy AN, Twaroski K, Lonetree CL, DeFeo AP, et al. CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. NPJ Regen Med 2016;1:16104.
- Yazdi AS, Guarda G, Riteau N, Drexler SK, Tardivel A, Couillin I, et al. Nanoparticles activate the NLR pyrin domain containing 3 (NIrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta. Proc Natl Acad Sci USA 2010;107:19449–54.
- Yu CH, Moecking J, Geyer M, Masters SL. Mechanisms of NLRP1-mediated autoinflammatory disease in humans and mice. J Mol Biol 2018;430: 142–52.
- Zare S, Zarei MA, Ghadimi T, Fathi F, Jalili A, Hakhamaneshi MS. Isolation, cultivation and transfection of human keratinocytes. Cell Biol Int 2014;38: 444–51.
- Zhang F, Wen Y, Guo X. CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet 2014;23(R1):R40-6.
- Zhong FL, Mamai O, Sborgi L, Boussofara L, Hopkins R, Robinson K, et al. Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation. Cell 2016;167: 187–202.